clinical trial · NCT06974994
Resilience to Antibiotic-induced Obesogenic Microbiota: Discovering Mechanism of Microbiota Modulation
Turku University Hospital·N/A·recruiting·n = 125
Healthy Newborn InfantsSynbiotic SupplementPlacebo
brief summary
The aim is to study whether the microbiota of children who are exposed to antibiotics at birth could be modified by synbiotic supplement and thereby reduce the risk of obesity, chronic diseases and respiratory tract infections. A total of 125 mother-child pairs will be recruited in this randomized, double-blind, placebo-controlled study. Infants are randomized to receive either a synbiotic supplement or a placebo for 2 months, after which their growth and morbidity will be monitored at the research clinic for 2 years.
started
May 8, 2024
primary completion
Dec 1, 2029
completion
Dec 1, 2029
last updated
May 16, 2025
official title
Resilience to Antibiotic-induced Obesogenic Microbiota Vertically Transferred to the Neonatal Gut: Discovering Mechanism of Microbiota Modulation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol